WO2012006149A3 - Analogs of c5a and methods of using same - Google Patents

Analogs of c5a and methods of using same Download PDF

Info

Publication number
WO2012006149A3
WO2012006149A3 PCT/US2011/042344 US2011042344W WO2012006149A3 WO 2012006149 A3 WO2012006149 A3 WO 2012006149A3 US 2011042344 W US2011042344 W US 2011042344W WO 2012006149 A3 WO2012006149 A3 WO 2012006149A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
methods
same
carboxy
infection
Prior art date
Application number
PCT/US2011/042344
Other languages
French (fr)
Other versions
WO2012006149A2 (en
Inventor
Sam D. Sanderson
Joy Arlene Phillips
Edward Leroy Morgan
Marilyn Louise Thoman
Tamsin Sheen
Kelly S. Doran
Elizabeth Louise Virts
Tammy Kielian
Mark Hanke
Original Assignee
Board Of Regents Of The University Of Nebraska
San Diego State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents Of The University Of Nebraska, San Diego State University Research Foundation filed Critical Board Of Regents Of The University Of Nebraska
Priority to US13/806,250 priority Critical patent/US9895411B2/en
Priority to AU2011276445A priority patent/AU2011276445A1/en
Priority to EP11804175.5A priority patent/EP2588121A4/en
Priority to CA2839677A priority patent/CA2839677A1/en
Publication of WO2012006149A2 publication Critical patent/WO2012006149A2/en
Publication of WO2012006149A3 publication Critical patent/WO2012006149A3/en
Priority to US15/869,396 priority patent/US10363282B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Materials and methods for treating and preventing an infection or disease, and for directly killing microorganisms, using carboxy-terminal C5a analogs, are provided.
PCT/US2011/042344 2010-06-29 2011-06-29 Analogs of c5a and methods of using same WO2012006149A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/806,250 US9895411B2 (en) 2010-06-29 2011-06-29 Analogs of C5a and methods of using same
AU2011276445A AU2011276445A1 (en) 2010-06-29 2011-06-29 Analogs of C5a and methods of using same
EP11804175.5A EP2588121A4 (en) 2010-06-29 2011-06-29 Analogs of c5a and methods of using same
CA2839677A CA2839677A1 (en) 2010-06-29 2011-06-29 Analogs of c5a and methods of using same
US15/869,396 US10363282B2 (en) 2010-06-29 2018-01-12 Analogs of C5a and methods of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35944410P 2010-06-29 2010-06-29
US61/359,444 2010-06-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/806,250 A-371-Of-International US9895411B2 (en) 2010-06-29 2011-06-29 Analogs of C5a and methods of using same
US15/869,396 Division US10363282B2 (en) 2010-06-29 2018-01-12 Analogs of C5a and methods of using same

Publications (2)

Publication Number Publication Date
WO2012006149A2 WO2012006149A2 (en) 2012-01-12
WO2012006149A3 true WO2012006149A3 (en) 2012-05-10

Family

ID=45441748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/042344 WO2012006149A2 (en) 2010-06-29 2011-06-29 Analogs of c5a and methods of using same

Country Status (5)

Country Link
US (2) US9895411B2 (en)
EP (1) EP2588121A4 (en)
AU (1) AU2011276445A1 (en)
CA (1) CA2839677A1 (en)
WO (1) WO2012006149A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006149A2 (en) * 2010-06-29 2012-01-12 Board Of Regents Of The University Of Nebraska Analogs of c5a and methods of using same
WO2013082535A2 (en) * 2011-12-02 2013-06-06 Board Of Regents Of The University Of Nebraska Controlled-release peptide compositions and uses thereof
ES2441880B1 (en) * 2012-07-06 2014-11-13 Universidad De Granada COMPOSITION BASED ON POLIPEPTIDES FOR THE TREATMENT OF MIASIS
AU2016228771A1 (en) 2015-03-11 2017-10-26 Board Of Regents Of The University Of Nebraska Conformationally stable analogs of the response selective C5a agonist EP67
BR112019026336A2 (en) * 2017-06-12 2020-07-21 Board Of Regents Of The University Of Nebraska hydrochloride salt form of a c5a c-terminal analog peptide and the use thereof, composition, method to induce an immune response against an infection or cancer, kit and compound to increase an immune response to an immunogenic agent
WO2019154515A1 (en) 2018-02-09 2019-08-15 The Cyprus Foundation For Muscular Dystrophy Research Methods and compositions for the treatment of amyloid diseases
CN108558994B (en) * 2018-04-17 2021-05-11 中国科学院海洋研究所 Portunus trituberculatus C1q receptor PtgC1qR gene and encoding protein and application thereof
US11911464B2 (en) 2018-09-14 2024-02-27 Prommune, Inc. Anti-parasitic immunological compositions
CN112190707A (en) * 2020-09-16 2021-01-08 河南有为医药科技有限公司 anti-HPV recombinant human gel and preparation method thereof
WO2023056527A1 (en) * 2021-10-07 2023-04-13 The University Of Queensland Proteinaceous molecules and uses therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
US20060160726A1 (en) * 1997-06-25 2006-07-20 The University Of Queensland Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
US20080058252A1 (en) * 2002-04-08 2008-03-06 Taylor Stephen M Use of C5A receptor antagonist in the treatment of fibrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387671A (en) * 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
WO1996005226A1 (en) * 1994-08-16 1996-02-22 Human Genome Sciences, Inc. POLYNUCLEOTIDE ENCODING C5a RECEPTOR
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
EP0859625B1 (en) * 1995-10-20 2008-06-25 University Of Nebraska Board Of Regents Composition and methods for enhancing immune responses mediated by antigen-presenting cells
WO2012006149A2 (en) * 2010-06-29 2012-01-12 Board Of Regents Of The University Of Nebraska Analogs of c5a and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
US20060160726A1 (en) * 1997-06-25 2006-07-20 The University Of Queensland Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
US20080058252A1 (en) * 2002-04-08 2008-03-06 Taylor Stephen M Use of C5A receptor antagonist in the treatment of fibrosis

Also Published As

Publication number Publication date
CA2839677A1 (en) 2012-01-12
US9895411B2 (en) 2018-02-20
EP2588121A2 (en) 2013-05-08
EP2588121A4 (en) 2013-12-04
WO2012006149A2 (en) 2012-01-12
AU2011276445A1 (en) 2013-02-21
US20150297668A1 (en) 2015-10-22
US20180140659A1 (en) 2018-05-24
US10363282B2 (en) 2019-07-30

Similar Documents

Publication Publication Date Title
WO2012006149A3 (en) Analogs of c5a and methods of using same
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
UA110199C2 (en) Solid rifaximin dispersion
EP2558493A4 (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
WO2011005595A3 (en) 2-5a analogs and their methods of use
WO2011049987A3 (en) Azaindazoles to treat flaviviridae virus infection
TR201813877T4 (en) COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY.
WO2014052836A3 (en) Methods and compositions for treating infection
NZ602544A (en) Crystalline forms of a macrolide, and uses therefor
SG178952A1 (en) Chemical compounds
WO2010083347A3 (en) Peptidomimetic macrocycles
EA025278B9 (en) Antiviral composition against dna or rna enveloped or non-enveloped viruses
MX356210B (en) Acrylic polymer formulations.
ZA201101814B (en) Prevention, treatment and diagnosis of p.gingivalis infection
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
WO2012119070A3 (en) Silicone-based ophthalmic formulations
EP2601967A4 (en) Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
SG10201704908SA (en) Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection
WO2013120022A3 (en) Treatment of hypoglycemia
WO2012103295A3 (en) Small molecule rnase inhibitors and methods of use
WO2011163566A3 (en) Methods of treating patients with immune-related diseases
IN2013MN00733A (en)
WO2011029536A3 (en) Use of cyclic keto-enols for combating plant pathogenic bacteria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11804175

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011804175

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011276445

Country of ref document: AU

Date of ref document: 20110629

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13806250

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2839677

Country of ref document: CA